登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600654 证券简称：中安科 公告编号：2026-004 中安科股份有限公司 第四季度自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次行权股票数量：2025年第四季度，中安科股份有限公司（以下简称"公司"）《2023年股票期权与 限制性股票激励计划》（以下简称"本激励计划""激励计划"）授予股票期权第二个行权期行权且完成股 份登记的期权数量合计为1,170,480股，占第二个行权期可行权股票期权总数的60.96%。 ● 截至2025年第四季度末，公司《激励计划》授予股票期权第二个行权期累计行权且完成股份过户登记 的行权股票数量为1,883,021股，占第二个行权期可行权股票期权总数的98.07%。 ● 本次行权股票上市流通时间：采用自主行权模式，激励对象行权所得股票于行权日（T日）后的第二 个交易日（T+2）日上市交易。 一、本激励计划已履行的决策程序及相关信息披露 1、2023年3月17日，公司召开第十一届董事会 ...

Group 1 - The company will hold its third extraordinary general meeting of 2025 on December 31, 2025, with both on-site and online voting options available for shareholders [2][3][6] - The meeting will discuss several key resolutions, including changes to the company's registered capital and amendments to the articles of association [7][50] - The company has set a record date of December 25, 2025, for shareholders eligible to attend the meeting [3][6] Group 2 - The company announced the cancellation of 167,252 stock options from its 2021 stock option and restricted stock incentive plan due to 24 incentive recipients not exercising their options within the valid period [27][40][41] - The decision to cancel the stock options was made during the 17th meeting of the sixth board of directors held on December 15, 2025, and complies with relevant regulations [41][42][43] - The cancellation of stock options is not expected to significantly impact the company's financial status or operational performance [42][44] Group 3 - The company approved changes to its registered capital, increasing it from 2,311,692,581 shares to 2,311,847,493 shares due to stock option exercises [72] - Amendments to the articles of association were made in accordance with the revised Company Law and the 2025 Listing Rules [73]

（文章来源：证券日报） 证券日报网讯 12月12日晚间，长亮科技发布公告称，公司董事会同意对2023年股票期权与限制性股票 激励计划中1名不符合解锁条件的激励对象已获授但尚未解除限售的限制性股票3200股进行回购注销， 本次限制性股票回购注销完成后，将导致公司股本总额减少3200股、公司注册资本减少3200元。 ...

Core Points - The company has announced the second exercise period for its 2021 stock option and restricted stock incentive plan, allowing for the exercise of 738,491 shares from December 25, 2024, to November 24, 2025, with 278,530 shares exercised to date, representing 37.72% of the total available for this period [1][18][19] Decision-Making Process and Disclosure - On November 18, 2021, the company held its fourth board meeting, approving several proposals related to the stock option and restricted stock incentive plan, with independent directors expressing their agreement [1][2][3] - The company also held a temporary shareholders' meeting on December 6, 2021, where over two-thirds of the voting rights approved the same proposals [3] Adjustments and Approvals - On August 15, 2022, the company adjusted the number and price of the stock options and restricted stocks in the incentive plan [4] - The company completed the registration of 1,564,662 stock options on November 25, 2022 [6] Exercise and Trading Arrangements - The stock options will be exercised through a self-exercise method, with shares reaching the accounts of the incentive participants on the first trading day after the exercise date [18] - The total number of shares exercised as of November 24, 2025, is 278,530, with the total funds raised amounting to 6,328,201.60 yuan [19] Impact on Financial Reports - The exercise of these stock options is not expected to have a significant impact on the company's financial condition or operating results [19]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603538 证券简称：美诺华 公告编号：2025-112 重要内容提示： ● 本次行权股票数量：2021年股票期权与限制性股票激励计划预留授予股票期权第二个行权期可行权数 量为738,491股，行权期为2024年12月25日至2025年11月24日。截至2025年11月24日，累计行权278,530 股，占预留授予股票期权第二个行权期可行权总量的37.72%。 ● 本次行权股票上市流通时间：公司本次行权方式为自主行权，激励对象行权所得股票于行权日（T 日）后的第一个交易日（T+1日）到达股票账户，并于第二个交易日（T+2日）上市交易。 一、本次股票期权行权的决策程序及相关信息披露 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于2021年股票期权与限制性股票激励计划预留授予 第二个行权期自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 4、2022年8月15日，公司召开第四届董事会第十一次会议、第四届监事会第十次 ...

Core Viewpoint - The company has completed the cancellation of unexercised stock options from the second exercise period of its 2022 stock option and restricted stock incentive plan, totaling 1,161,500 options due to 23 incentive recipients not exercising their options by the deadline [2][15][16]. Summary by Sections Incentive Plan Overview - The 2022 stock option and restricted stock incentive plan was approved by the company's board on August 4, 2022, and involved granting 23,880,000 stock options at an exercise price of 6.17 yuan per share and 15,920,000 restricted shares at a price of 3.86 yuan per share [5][6]. Cancellation of Stock Options - The second exercise period for the stock options was from October 23, 2024, to September 29, 2025. As of the deadline, 1,161,500 stock options remained unexercised and were subsequently canceled [16][18]. - The company has completed the necessary procedures for the cancellation of these stock options with the China Securities Depository and Clearing Corporation [3][17]. Impact on Company Performance - The cancellation of these stock options is not expected to have a significant impact on the company's financial status or operational results, nor will it affect the implementation of the incentive plan or the motivation and stability of the management team [18].

Core Points - The company announced restrictions on the exercise period for stock options under its 2023 stock option and restricted stock incentive plan [1] Summary by Sections Stock Option Exercise Period - The actual exercise period for the second exercise phase of the stock options (option code: 1000000399) is set from July 24, 2025, to June 29, 2026, and is currently in the exercise stage [1] - The actual exercise period for the first exercise phase of the reserved stock options (option code: 1000000530) is from December 18, 2024, to November 29, 2025, and is also currently in the exercise stage [1] Restriction Period - A restriction on the exercise period will be in effect from October 22, 2025, to October 26, 2025, during which all incentive objects for the stock options (codes: 1000000399 and 1000000530) will be restricted from exercising [1] - The company will apply to the Shanghai branch of China Securities Depository and Clearing Corporation Limited for the relevant matters regarding the restriction on exercise in accordance with regulations [1]

Group 1 - The core viewpoint of the article highlights that XCMG Machinery has announced a significant stock option and restricted stock incentive plan for 2025, marking one of the largest equity incentive plans in the machinery industry, aiming to become a global leader in engineering machinery [1] - The company plans to grant incentives to no more than 4,700 individuals, with a total of 470 million shares to be awarded, accounting for approximately 4% of the company's total equity [1] - The initial grant will consist of 423 million shares, representing 3.6% of the total equity and 90% of the total incentives planned [1] Group 2 - The company's performance for the first half of 2025 is stable, with adjustments in "four structures" contributing to high-quality development [1] - The engineering machinery industry is showing signs of recovery, with domestic excavator sales increasing by 22% year-on-year and exports rising by 13% from January to July [1] - Major infrastructure projects such as the Yaxi Hydropower Station and the New Tibet Railway are expected to boost domestic demand for engineering machinery, positioning the company to benefit from this trend [1]

Core Viewpoint - The board's remuneration and assessment committee of XCMG Group has reviewed and approved the draft of the 2025 stock option and restricted stock incentive plan, concluding that it is beneficial for the company's sustainable development and does not harm the interests of all shareholders [1][4]. Group 1: Eligibility for Implementation - The company meets the qualifications for implementing the stock incentive plan, having not received negative audit opinions on financial reports or internal controls in the last accounting year [1][2]. - There have been no instances in the last 36 months where profit distribution was not conducted according to laws, regulations, or company commitments [1][2]. - The incentive plan does not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares [2]. Group 2: Compliance with Regulations - The granting and exercise of stock options/restricted stocks comply with relevant laws and regulations, ensuring no harm to the company and all shareholders [2][3]. - The plan aims to create a mechanism that aligns the interests of employees and shareholders, promoting sustainable development for the company [3][4].

Core Viewpoint - XCMG Machinery (000425.SZ) announced a stock option and restricted stock incentive plan for 2025, which includes a total of 47 million shares to be granted, representing 4% of the company's total share capital as of the announcement date [1] Summary by Category - **Incentive Plan Details** - The incentive plan consists of stock option and restricted stock components [1] - The initial exercise price for stock options is set at 9.67 yuan per share, while the grant price for restricted stocks is 4.84 yuan per share [1] - **Share Allocation** - A total of 47 million shares will be granted to the incentive recipients, which is approximately 4% of the company's total share capital of 1,175,297.25 million shares [1]